MARKET

ABIO

ABIO

ARCA BIOPHARMA
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.01
-0.13
-2.53%
Closed 16:00 10/14 EDT
OPEN
5.20
PREV CLOSE
5.14
HIGH
5.20
LOW
5.01
VOLUME
21.51K
TURNOVER
--
52 WEEK HIGH
20.45
52 WEEK LOW
4.725
MARKET CAP
7.29M
P/E (TTM)
-0.7180
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of ABIO and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

ABIO News

  • ARCA Biopharma President and CEO Dr. Michael Bristow to Present at HFSA 2019 Excellence in Translational Science Symposium
  • GlobeNewswire.09/12 13:30
  • 71 Biggest Movers From Yesterday
  • Benzinga.09/12 09:33
  • ARCA Bio up 19% premarket ahead of presentation of Gencaro data
  • seekingalpha.09/11 18:05
  • 48 Stocks Moving In Wednesday's Mid-Day Session
  • Benzinga.09/11 16:27

More

Industry

Pharmaceuticals
-0.01%
Pharmaceuticals & Medical Research
+0.09%

Hot Stocks

Name
Price
%Change

About ABIO

ARCA biopharma, Inc. (ARCA) is a biopharmaceutical company. The Company is principally focused on developing genetically-targeted therapies for cardiovascular diseases. The Company's lead product candidate is Gencaro (bucindolol hydrochloride), a beta-blocker and mild vasodilator that the Company is evaluating in a clinical trial for the treatment of atrial fibrillation (AF) in patients with heart failure with reduced left ventricular ejection fraction (HFREF). Gencaro is considered part of the beta-blocker class of compounds because of its property of blocking both beta-1 and beta-2, receptors in the heart. The blocking of these receptors prevents the receptor from binding with other molecules, primarily the neurotransmitter norepinephrine (NE), which activate these receptors. The Company is conducting a Phase IIB/III clinical trial of Gencaro, known as GENETIC-AF.
More

Webull offers Arca Biopharma Inc (ABIO) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.